Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
SEC Accession No. 0000950170-25-038262
Filing Date
2025-03-12
Accepted
2025-03-12 20:30:02
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13D/A  
1 primary_doc.xml SCHEDULE 13D/A 6966
  Complete submission text file 0000950170-25-038262.txt   8340
Mailing Address
Business Address
BLATT LAWRENCE (Filed by) CIK: 0001242110 (see all company filings)

Type: SCHEDULE 13D/A

Mailing Address ONE CORPORATE DR., 2ND FLOOR SOUTH SAN FRANCISCO CA 94080
Business Address ONE CORPORATE DR., 2ND FLOOR SOUTH SAN FRANCISCO CA 94080 (800) 466-6059
Aligos Therapeutics, Inc. (Subject) CIK: 0001799448 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13D/A | Act: 34 | File No.: 005-91770 | Film No.: 25733467
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)